FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376803> ?p ?o ?g. }

• W4308376803 abstract "<h3>Background</h3> One of the top challenges in cancer immunotherapy is ‘understanding the molecular and cellular drivers of primary vs. secondary immune escape to immune checkpoint blockade therapies.’ Although durable responses indicating immunologic memory are reported, most patients do not respond with tumor regression. In addition, recurrences are observed after initial response, suggesting the emergence of acquired resistance. Therefore, novel therapeutics are needed to enhance ICB treatment to halt melanoma progression and increase patient survival rates. Oxidative stress and hypoxia in the tumor microenvironment resulting in endoplasmic reticulum (ER) stress signaling associated with cancer therapy resistance. PKR-like endoplasmic reticulum kinase actions in the tumor microenvironment can occur by activation of the Unfolded Response (UPR). However, PERK also has functions that are not linked to canonical activation of UPR signaling. PERK is involved in the maintenance of ER with mitochondria-associated membranes (MAMs). This is important in glucose sensing and could impair metabolic reprogramming during T cell activation if disrupted. <h3>Methods</h3> To determine ER-stress markers of patient response, we analyzed Peripheral Blood Mononuclear Cells by single-cell RNA sequencing (scRNAseq), 3D electron, and confocal microscopy to determine mitochondria/ER interactions. Antigen-mediated CD8+ T cell toxicity assay was performed using Pmel-1 transgenic mice. LC-MS Metabolomics and Seahorse mitochondrial respiration assays were used to determine CD8+ cellular energetics treated with anti-PD-1 in the presence or absence of PERK blockade. An in vivo murine tumor model (B16) was developed to determine whether PERK blockade sensitizes tumors to anti-PD1 therapy. <h3>Results</h3> UMAP clustering of our scRNAseq data indicates a ~3-fold increase in PERK expression after the first treatment cycle in patients who did not respond to anti-PD-1 therapy (n=12, *p<0.05). This was confirmed by plasma ELISA assay in a different cohort of patients (N=50, *p<0.001). Furthermore, the expression of PERK in non-responder patients was associated with increased expression of TOX1 in the T-cell population, and induction of ER stress caused a transcriptional increase in TOX1 in T cells suggesting that ER stress may be associated with T cell dysfunction. Induction of ER stress limited antigen-mediated CD8+ T cell killing; however, blockade of PERK enhanced the cytolytic capacity of CD8+ T cells over 4-fold, clearing tumor cells even under ER stress-induced circumstances (n=4, *p<0.01). Examination of ER-mitochondria interactions by confocal and 3D electron microscopy suggested increased co-localization of these two organelles in lymphocytes of responder patients to anti-PD1 therapy. Blockade of PERK in combination with anti-PD1 treatment resulted in a 64% reduction in tumor volume compared to control and an over 40% reduction compared to anti-PD1 monotherapy (n=7, *p<0.002). This suggests that blockade of PERK enhances αPD-1 efficacy. PCA from metabolomics of tumor-infiltrating T cells suggested a differential metabolic signature that separates the PD1 treated group from control, PERK blockade, and combination-treated animals. Furthermore, blockade of PERK increased glycolytic flux and mitochondrial respiration of CD8+ T cells. Thus, blockade of PERK supports metabolic reprogramming to support T cell effector function under ER stress conditions. <h3>Conclusions</h3> Our data show that PERK expression may serve as a potential clinical marker of ICB response. Our preliminary evidence indicates that Targeting PERK improved the efficacy of anti-PD1 therapy by modulating metabolic signaling of CD8+ T cells. Thus, targeting PERK in the tumor microenvironment may inhibit pro-oncogenic and immunosuppressive signaling from enhancing ICB responsiveness." @default.
• W4308376803 created "2022-11-11" @default.
• W4308376803 creator A5019670635 @default.
• W4308376803 creator A5025967603 @default.
• W4308376803 creator A5027276690 @default.
• W4308376803 creator A5049630935 @default.
• W4308376803 creator A5073497590 @default.
• W4308376803 creator A5076681721 @default.
• W4308376803 creator A5076699095 @default.
• W4308376803 creator A5087285442 @default.
• W4308376803 date "2022-11-01" @default.
• W4308376803 modified "2023-09-27" @default.
• W4308376803 title "178 Targeting ER-mitochondrial dynamics to improve responses to immune checkpoint blockade" @default.
• W4308376803 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0178" @default.
• W4308376803 hasPublicationYear "2022" @default.
• W4308376803 type Work @default.
• W4308376803 citedByCount "0" @default.
• W4308376803 crossrefType "proceedings-article" @default.
• W4308376803 hasAuthorship W4308376803A5019670635 @default.
• W4308376803 hasAuthorship W4308376803A5025967603 @default.
• W4308376803 hasAuthorship W4308376803A5027276690 @default.
• W4308376803 hasAuthorship W4308376803A5049630935 @default.
• W4308376803 hasAuthorship W4308376803A5073497590 @default.
• W4308376803 hasAuthorship W4308376803A5076681721 @default.
• W4308376803 hasAuthorship W4308376803A5076699095 @default.
• W4308376803 hasAuthorship W4308376803A5087285442 @default.
• W4308376803 hasBestOaLocation W43083768031 @default.
• W4308376803 hasConcept C126322002 @default.
• W4308376803 hasConcept C137061746 @default.
• W4308376803 hasConcept C139447449 @default.
• W4308376803 hasConcept C158617107 @default.
• W4308376803 hasConcept C167672396 @default.
• W4308376803 hasConcept C170493617 @default.
• W4308376803 hasConcept C202751555 @default.
• W4308376803 hasConcept C203014093 @default.
• W4308376803 hasConcept C2776090121 @default.
• W4308376803 hasConcept C2776107976 @default.
• W4308376803 hasConcept C2777701055 @default.
• W4308376803 hasConcept C2777877232 @default.
• W4308376803 hasConcept C2778468042 @default.
• W4308376803 hasConcept C2780851360 @default.
• W4308376803 hasConcept C28859421 @default.
• W4308376803 hasConcept C502942594 @default.
• W4308376803 hasConcept C55493867 @default.
• W4308376803 hasConcept C71924100 @default.
• W4308376803 hasConcept C86803240 @default.
• W4308376803 hasConcept C8891405 @default.
• W4308376803 hasConcept C95444343 @default.
• W4308376803 hasConceptScore W4308376803C126322002 @default.
• W4308376803 hasConceptScore W4308376803C137061746 @default.
• W4308376803 hasConceptScore W4308376803C139447449 @default.
• W4308376803 hasConceptScore W4308376803C158617107 @default.
• W4308376803 hasConceptScore W4308376803C167672396 @default.
• W4308376803 hasConceptScore W4308376803C170493617 @default.
• W4308376803 hasConceptScore W4308376803C202751555 @default.
• W4308376803 hasConceptScore W4308376803C203014093 @default.
• W4308376803 hasConceptScore W4308376803C2776090121 @default.
• W4308376803 hasConceptScore W4308376803C2776107976 @default.
• W4308376803 hasConceptScore W4308376803C2777701055 @default.
• W4308376803 hasConceptScore W4308376803C2777877232 @default.
• W4308376803 hasConceptScore W4308376803C2778468042 @default.
• W4308376803 hasConceptScore W4308376803C2780851360 @default.
• W4308376803 hasConceptScore W4308376803C28859421 @default.
• W4308376803 hasConceptScore W4308376803C502942594 @default.
• W4308376803 hasConceptScore W4308376803C55493867 @default.
• W4308376803 hasConceptScore W4308376803C71924100 @default.
• W4308376803 hasConceptScore W4308376803C86803240 @default.
• W4308376803 hasConceptScore W4308376803C8891405 @default.
• W4308376803 hasConceptScore W4308376803C95444343 @default.
• W4308376803 hasLocation W43083768031 @default.
• W4308376803 hasOpenAccess W4308376803 @default.
• W4308376803 hasPrimaryLocation W43083768031 @default.
• W4308376803 hasRelatedWork W1495108757 @default.
• W4308376803 hasRelatedWork W1994289493 @default.
• W4308376803 hasRelatedWork W3025204980 @default.
• W4308376803 hasRelatedWork W3034386412 @default.
• W4308376803 hasRelatedWork W3039388108 @default.
• W4308376803 hasRelatedWork W3115854654 @default.
• W4308376803 hasRelatedWork W3174769180 @default.
• W4308376803 hasRelatedWork W3177607563 @default.
• W4308376803 hasRelatedWork W4307607145 @default.
• W4308376803 hasRelatedWork W4309781227 @default.
• W4308376803 isParatext "false" @default.
• W4308376803 isRetracted "false" @default.
• W4308376803 workType "article" @default.